Eli Lilly (NYSE: LLY) Price Target Raised Amid Strong Growth and Pipeline Promise

• Leerink Partners has set a new price target for Eli Lilly (NYSE: LLY), indicating a 5.07% potential upside.
• Eli Lilly reported robust first-quarter 2026 revenue of $19.80 billion, driven by strong sales of Mounjaro and Zepbound.
• The company's drug pipeline, including promising late-stage data for retatrutide, positions Eli Lilly strongly in the competitive weight loss drug market.

On May 26, 2026, Leerink Partners set a new price target of $1,119 for Eli Lilly (NYSE: LLY). As highlighted by StreetInsider, this represents a 5.07% potential upside for the pharmaceutical stock from its price of $1,065. Eli Lilly is a global biopharmaceutical firm known for its focus on diabetes treatment and weight loss solutions.

The company's strong performance supports this positive investment analysis outlook. Eli Lilly reported first-quarter 2026 revenue of $19.80 billion, a 55.5% increase from the previous year. This significant revenue growth was driven by its popular drugs, Mounjaro, with $8.66 billion in sales, and Zepbound, with $4.16 billion.

Eli Lilly's drug pipeline also shows promise in drug development. The company reported positive late-stage data for its weight loss drug, retatrutide. Analysts at UBS noted its "solid strong weight loss efficacy," with data showing approximately 28 percent weight loss in patients at 80 weeks.

Eli Lilly operates in a highly competitive market projected to be worth $100 billion by the early 2030s. The company has surpassed rival Novo Nordisk, capturing 60% of the U.S. market share in this space. Other key players in this biopharmaceutical market include Viking Therapeutics and Pfizer.

Despite positive news and strong drug sales, Eli Lilly faces challenges, with its stock performance down 4.63% year-to-date. This is partly due to a 13% price drop for Mounjaro in China. The company also faces stiff competition from Novo Nordisk's Wegovy and a recent legal setback in a Medicaid fraud appeal, highlighting the competitive landscape.